Alzamend Neuro announces annual shareholder meeting

ALZN•2026-08-28

Adjournment authorization

An additional proposal seeks authorization to adjourn the meeting to allow more time to solicit votes.

Preferred stock conversion proposal

Investors will decide on converting Series D convertible preferred stock into common stock under a financing of up to USD 25 million.

Annual meeting scheduled for Oct. 19, 2026

Alzamend Neuro plans a virtual annual shareholder meeting on Oct. 19, 2026.

Shareholders will vote to elect six directors to serve until the 2028 annual meeting. Ballots also cover auditor ratification for the fiscal year ending Apr. 30, 2027.

Sources

Alzamend Neuro announces annual shareholder meeting

Sec

Alzamend Neuro announces annual shareholder meeting

Adjournment authorization

Preferred stock conversion proposal

Annual meeting scheduled for Oct. 19, 2026

Related News

Spero Therapeutics inks Jefferies at-the-market equity distribution deal for up to $100 million

SiteOne CEO Doug Black reports $480,650 acquisition of common shares

Novanta CFO, medical solutions COO to present at Baird Global Healthcare Conference

Sources

Alzamend Neuro announces annual shareholder meeting

Andretti Acquisition Corp. II special meeting adjourned without conducting business

Microchip files Form 3 for Sr. Corp VP Stephanus Duvenhage